Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes

Biomedicines, Free Full-Text

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Menin inhibitor treatment depletes H3K27 acetyl mark on chromatin

Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches

MEN1 mutations confer resistance to menin inhibitor treatment in

Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia - The Lancet Haematology

Therapeutic implications of menin inhibition in acute leukemias

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet Haematology

Cancers, Free Full-Text

Study Unearths Cause of Resistance to New Drug for Acute Leukemia

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia